Danaher Corp
Close on Nov 2, 2026Market cap $160.26BP/E 40.5Yield –
Danaher Biotechnology — Core Sales Growth by Quarter
Biotechnology — Core Sales Growth (%) (%)
Danaher Biotechnology — Core Sales Growth: 5.0% in Q3 2026, down 1.5 pts from a year earlier.
Where the Q3 2026 figure comes from
Source: Danaher IR — nongaap_2026Q3 ↗
Includes Cytiva and Pall Biotech (consumables, bioprocess filtration/chromatography equipment, and cell culture).
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Biotechnology — Core Sales Growth (%) (%) | Year on year | Source |
|---|---|---|---|---|
| Q3 2026 | Sep 30, 2026 | 5.0% | -1.5 pts | Danaher IR — nongaap_2026Q3 ↗ |
| Q2 2026 | Jun 30, 2026 | 2.5% | -3.5 pts | Danaher IR — nongaap_2026Q2 ↗ |
| Q1 2026 | Mar 31, 2026 | 7.0% | 0.0 pts | Danaher IR — nongaap_2026Q1 ↗ |
| Q4 2025 | Dec 31, 2025 | 6.0% | -2.0 pts | Danaher IR — nongaap_2025Q4 ↗ |
| Q3 2025 | Sep 30, 2025 | 6.5% | +6.5 pts | Danaher IR — nongaap_2025Q3 ↗ |
| Q2 2025 | Jun 30, 2025 | 6.0% | +13.0 pts | Danaher IR — nongaap_2025Q2 ↗ |
| Q1 2025 | Mar 31, 2025 | 7.0% | +24.0 pts | Danaher IR — nongaap_2025Q1 ↗ |
| Q4 2024 | Dec 31, 2024 | 8.0% | +30.5 pts | Danaher IR — nongaap_2024Q4 ↗ |
| Q3 2024 | Sep 30, 2024 | 0.0% | +21.0 pts | Danaher IR — nongaap_2024Q3 ↗ |
| Q2 2024 | Jun 30, 2024 | -7.0% | +9.5 pts | Danaher IR — nongaap_2024Q2 ↗ |
| Q1 2024 | Mar 31, 2024 | -17.0% | -4.0 pts | Danaher IR — nongaap_2024Q1 ↗ |
| Q4 2023 | Dec 31, 2023 | -22.5% | -26.5 pts | Danaher IR — nongaap_2023Q4 ↗ |
| Q3 2023 | Sep 30, 2023 | -21.0% | -26.5 pts | Danaher IR — nongaap_ex_veralto ↗ |
| Q2 2023 | Jun 30, 2023 | -16.5% | -25.0 pts | Danaher IR — nongaap_ex_veralto ↗ |
| Q1 2023 | Mar 31, 2023 | -13.0% | -19.5 pts | Danaher IR — nongaap_ex_veralto ↗ |
| Q4 2022 | Dec 31, 2022 | 4.0% | -25.5 pts | Danaher IR — nongaap_ex_veralto ↗ |
| Q3 2022 | Sep 30, 2022 | 5.5% | – | Danaher IR — nongaap_ex_veralto ↗ |
| Q2 2022 | Jun 30, 2022 | 8.5% | – | Danaher IR — nongaap_ex_veralto ↗ |
| Q1 2022 | Mar 31, 2022 | 6.5% | – | Danaher IR — nongaap_ex_veralto ↗ |
| Q4 2021 | Dec 31, 2021 | 29.5% | – | Danaher IR — nongaap_ex_veralto ↗ |
Breakdown
What makes up biotechnology — Core Sales Growth
Cite this data
StockData. (2026). Danaher Biotechnology — Core Sales Growth (%), quarterly Q4 2021–Q3 2026 [Data set]. Compiled from Danaher SEC filings and investor materials. https://stockdatahq.com/stocks/dhr/kpis/core-sales-growth-biotech
See every metric in the Danaher KPI table. Data updated Nov 2, 2026.